Vertex and Genomics plc forms a three-year collaboration extendable up to five years for Precision Medicines
Vertex and Genomics plc forms a three-year collaboration extendable up to five years for Precision Medicines
Shots:
- This collaboration plans to use human genetics and machine learning to address unmet needs by developing precision medicines
- Vertex will make £25M series B funding in Genomics (£10.5M equity investment) in addition to milestone and royalty payments from clinical developments to Genomics
- Genomics with its largest unique analysis engine having 100B data points linking human genetic variation over 14M position in human genome to changes in 7k disease outcomes
Click here to read full press release/ article | Ref: Vertex | Image: Xconomy
